Skip to content
Skip to navigation menu

 

Dr Emma Kidd  -  BSc PhD


General

Coordinator of the School's Pharmacology & Physiology Research Discipline

 

Research Interests

I am currently developing therapeutic antibodies as potential treatments for Alzheimer’s disease as current drugs are limited to treating the symptoms and do not affect the underlying disease process.

In addition, I am interested in the trafficking in cells of amyloid precursor protein from which β-amyloid, thought to be the main causative agent of Alzheimer’s disease, is derived. More information

 

Endocytosis and Alzheimer’s disease

Evidence is accumulating to suggest that changes in endocytosis may be involved in the pathogenesis of Alzheimer’s disease. We are currently investigating the importance of a number of endocytic proteins involved in clathrin- and non-clathrin-dependent endocytosis in the processing and trafficking of amyloid precursor protein, a key protein in the pathogenesis of this disease.

 

Adenosine receptors can have both proliferative and anti-proliferative effects on many types of tumour cells. We are interested in particular in their effects on breast cancer cells sensitive and resistant to the important anti-hormone, tamoxifen.

 

Myocardial infarction is a major cause of morbidity and mortality in the Western World and there is much interest in understanding more about the pathophysiological mechanisms involved and the development of novel treatments.

 

I am interested in studying the distribution and function of P2X receptors, the ligand-gated ion channels activated by ATP and adenosine receptors. These receptors have many important physiological and pathophysiological roles in the brain and the periphery.

 

We are interested in the role of P2X7 receptors in human osteoblasts, bone-forming cells. There is some controversy in the literature concerning the expression of these receptors on osteoblasts and our work has been directed at investigating this in more detail.

 

Trace amines were thought to be limited to the brain but we have obtained data showing that they may have physiological effects in the periphery. I am interested in learning more about these effects and whether they could be involved in the pathophysiology of a number of conditions in the heart, vasculature, lungs and gastrointestinal tract.

 

I am involved in the development of animal models of asthma which more closely the mimic human disease. Such models will allow us to learn more about the pathophysiology of this condition and may lead to novel or improved therapeutic drugs.  See also:

  

Collaborators

Postdoctoral Research Associates

  • Dr Rhys Evans (funded by RespiVert Ltd.)
  • Dr Amy Herbert (funded by the British Heart Foundation)
  • Dr Rhian Thomas (funded by BRACE)
  • Dr Dawn Turner (funded by Almirall S.A.)

 

School of Pharmacy and Pharmaceutical Sciences

  • Prof Ken Broadley, Pharmacology & Physiology
  • Dr Will Ford, Pharmacology & Physiology
  • Dr Arwyn Jones, Pharmaceutical Biology
  • Dr Claire Simons, Medicinal Chemistry

 

Cardiff University

  • Dr Joachim Bugert, Department of Infection, Immunity & Biochemistry
  • Dr Bronwen Evans, Department of Child Health
  • Dr Mark Good, School of Psychology
  • Dr Iain Hutcheson, Department of Pharmacology, Radiology and Oncology
  • Dr Lesley Jones, Institute of Medical Genetics
  • Dr Eryl Liddell, School of Biosciences
  • Prof Mike Owen, Department of Psychological Medicine
  • Prof. Julie Williams, Department of Psychological Medicine

 

External

  • Dr Tony Nials, GlaxoSmithKline, Stevenge, U.K.
  • Dr Garth Rappaport, Dr Pete Strong and Dr Lindsey Cass, RespiVert Ltd., London, U.K.
  • Dr Jorge Dealba. Gonzalezand Dr Montse Miralpeix, Almirall S.A., Barcelona, Spain
  • Dr Nicolay Ferrari and Dr Luc Paquet, TOPIGEN Pharmaceutical Inc., Montreal, Canada
  • Dr Manlio Bolla and Dr Emmet Purtill, NicOx, Sophia Antipolis, France
  • Dr Golde and Dr Eckman, Mayo Clinic, Jacksonville, Florida, U.S.A.
  • Prof. Christian Haass, Ludwig-Maximilians Universitat, Munich, Germany.

  

Key Expertise

  • Enzyme assays
  • Western blotting
  • Immunocytochemistry and immunohistochemistry with bright field and fluorescent microscopy including laser scanning confocal microscopy
  • ELISA
  • HPLC
  • Cell proliferation techniques
  • RT-PCR
  • In situ hybridisation
  • In vivo measurements of lung function

Current Research Funding

Project grants

  • Bristol Research into Alzheimer’s and Care of the Elderly (BRACE) Pilot Grant, Nov. 2010 – Oct. 2011, ‘The role of caveolins in the processing of amyloid precursor protein’, E.J. Kidd, £61,226.
  • British Heart Foundation Project Grant, Oct. 2009-Sept. 2012, ‘Roles of trace amine-associated receptors in cardiovascular responses to dietary trace amines’, W.R. Ford, K.J. Broadley and E.J. Kidd, £182,805.

Ph.D. studentships

  • Indonsesian Government Ph.D. Studentship, Jan. 2010 – Dec. 2012, ‘Mechanisms of resistance to steroid actions in the airways’, K.J. Broadley, E.J. Kidd and W.R. Ford, £103,106.
  • GlaxoSmithKline MRC Industrial CASE Ph.D. Studentship, Oct. 2009-Sept. 2012, ‘Roles of viral and bacterial infection in asthma exacerbations and steroid resistance’, K.J. Broadley, E.J. Kidd and W.R. Ford, £79,300.
  • Novartis BBSRC Industrial CASE Ph.D. Studentship, Oct. 2009-Sept. 2013, ‘In vivo examination of viral exacerbations of airways inflammation, function, mucus hypersecretion and mucociliary clearance’, K.J. Broadley, E.J. Kidd, W.R. Ford and J.J. Bugert, £105,910.
  • Alzheimer’s Society PhD studentship, Oct. 2008-Sept. 2011, ‘An evaluation of steric hindrance of APP processing by 2B12 as a treatment for amyloid-related pathology in a murine preclinical model of Alzheimer’s disease’, M. Good and E.J. Kidd, £84,897.
  • British Council Ph.D. studentship Oct. 2007-Sept. 2010, ‘Isolation and chemical and Pharmacological characterization of potential trace amine receptor antagonists from plant sources’, K.J. Broadley, W.R. Ford and E.J. Kidd, £50,850.

Research Contracts

  • Almirall S.A., April 2010-March 2011, Preliminary investigations of drug efficacy against ovalbumin and PIV3 induced airway inflammation’, Ford, W., E.J. Kidd and K.J. Broadley, £140,823.
  • GlaxoSmithKline, February 2010-November 2010, ‘Preliminary investigations of drug efficacy against ovalbumin-induced airway inflammation’, Ford, W., E.J. Kidd and K.J. Broadley, £72,553.
  • RespiVert Ltd., September 2008-January 2012, ‘Studies on the exacerbation of pulmonary inflammation by viral infection’, Ford, W., E.J. Kidd and K.J. Broadley, £354,681.